Financial Performance - The Group's profit after tax increased from approximately RMB 17,835,000 for the corresponding period of last year to approximately RMB 31,090,000 for the Reporting Period, representing an increase of approximately 74.32%[17] - Profit attributable to the owners of the Company increased from approximately RMB 20,344,000 for the corresponding period of last year to approximately RMB 29,881,000 for the Reporting Period, representing an increase of approximately 46.88%[17] - For the six months ended June 30, 2023, the profit attributable to owners of the Company was approximately RMB29,881,000, compared to RMB20,344,000 for the same period in 2022, representing an increase of 46.8%[80] - Basic earnings per share for the six months ended June 30, 2023, was RMB0.0178, up from RMB0.0121 for the same period in 2022, reflecting a growth of 47.1%[80] - Profit before taxation for the six months ended June 30, 2023, was RMB 36,474,000, up 44.2% from RMB 25,281,000 in the same period of 2022[122] - Profit and total comprehensive income for the period attributable to owners of the company was RMB 29,881,000 for the six months ended June 30, 2023, compared to RMB 20,344,000 in 2022[124] - For the six months ended June 30, 2023, the total comprehensive income was RMB 31,090, an increase from RMB 17,835 for the same period in 2022, representing a growth of 74.5%[128] Revenue and Sales - Revenue for the six months ended June 30, 2023, was RMB 555,531,000, an increase of 26.6% compared to RMB 438,869,000 for the same period in 2022[122] - Revenue from the manufacturing and selling of medicines was RMB 407,492,000, up 31.4% from RMB 310,182,000 year-on-year[160] - The sales and distribution of medicines and healthcare products generated RMB 148,039,000 in revenue, an increase from RMB 128,687,000 in the previous year[160] - For the six months ended June 30, 2023, total revenue reached RMB 555,531,000, a 26.6% increase from RMB 438,869,000 in the same period of 2022[160] - The reportable segment revenue was RMB 602,183,000, an increase from RMB 461,618,000 in the same period of 2022, representing a growth of approximately 30.4%[171] Expenses and Costs - The Group's sales and distribution expenses during the Reporting Period amounted to approximately RMB147,759,000, representing an increase of approximately 36.55% compared to RMB108,208,000 in the same period last year[39] - Other operating expenses totaled approximately RMB24,053,000, reflecting an increase of approximately 15.97% from RMB20,740,000 for the corresponding period of last year, primarily due to higher impairment of inventories and increased research and development expenses[40] - Staff costs, including directors' remuneration, amounted to approximately RMB73,137,000 during the Reporting Period, with salary increases and improved benefits implemented to maintain competitiveness[46] - Administrative expenses for the six months ended June 30, 2023, were RMB 41,207,000, slightly decreased from RMB 41,600,000 in 2022[122] Assets and Liabilities - Trade receivables as of June 30, 2023, amounted to RMB210,517,000, an increase from RMB177,007,000 as of December 31, 2022, representing a growth of 18.9%[82] - The total amount of trade and other receivables as of June 30, 2023, was RMB373,628,000, compared to RMB341,968,000 as of December 31, 2022, reflecting an increase of 9.3%[82] - Net current assets as of June 30, 2023, were RMB 551,898,000, an increase from RMB 482,366,000 at the end of 2022[127] - Total assets less current liabilities as of June 30, 2023, amounted to RMB 1,067,985,000, compared to RMB 1,035,507,000 at the end of 2022[127] - The company's total assets as of June 30, 2023, were RMB 1,036,394, an increase from RMB 962,235 at the end of June 2022, indicating a growth of 7.7%[128] - The total liabilities for reportable segments as of June 30, 2023, were RMB 664,537,000, a slight decrease from RMB 678,732,000 at the end of 2022[195] Inventory and Cash Flow - The Group's inventory write-down for the six months ended 30 June 2023 was RMB 6,013,000, compared to RMB 2,047,000 for the same period in 2022[2] - Inventories as of June 30, 2023, were RMB 222,779, an increase from RMB 203,023 at the end of June 2022, representing a rise of 9.7%[139] - The company reported a net cash used in operating activities of RMB 52,320 for the six months ended June 30, 2023, compared to a net cash generated of RMB 64,462 in the same period of 2022[143] - The company reported a net decrease in cash and cash equivalents of RMB 52,656,000 for the period, compared to an increase of RMB 40,113,000 in the same period last year[145] Research and Development - The Group has developed new medicines such as Doxofylline Injection and Concentrated Sodium Potassium Magnesium Calcium Injection, both of which have obtained approval[10] - The Group's research and development expenses are eligible for a super deduction of 200% for tax purposes, an increase from 175% in the previous year[94] - The group aims to enhance its market presence through ongoing research and development in modern biological technology[148] Corporate Governance - The Company confirmed compliance with Non-Competition Undertakings during the Reporting Period[55] - All Directors confirmed adherence to the "Required Standard of Dealings" and the Company's code of conduct regarding securities transactions[58] - The Company has adopted a code of conduct for securities transactions by Directors that meets the standards set out in the GEM Listing Rules[56] Shareholder Information - As of June 30, 2023, Neptunus Bio-engineering held approximately 73.51% of the entire issued share capital of the Company, with 70.38% directly held and 3.13% indirectly held through Shenzhen Neptunus Oriental Investment Company Limited[49] - Neptunus Group was deemed to be interested in 1,233,464,500 domestic shares of the Company, representing a significant portion of the issued share capital[52] - The Company has not adopted any share option schemes or granted any share options, convertible securities, warrants, or similar rights as of June 30, 2023[50] Taxation - The Group's subsidiaries in the PRC are subject to a preferential enterprise income tax rate of 15% due to their qualification as "High and New Technology Enterprises"[93] - The Group had no assessable profits subject to Hong Kong Profits Tax during the Reporting Period, maintaining a tax provision of zero[96]
海王英特龙(08329) - 2023 - 中期财报